Upperton is proud to announce that it has been recognised with two prestigious industry awards, winning the Quality Assurance & Control Award, and receiving Pharma Contract Services Company of the Year for the second consecutive year.
The awards recognise organisations that demonstrate excellence in pharmaceutical development and manufacturing services, celebrating businesses that consistently deliver outstanding client support, operational excellence, and the highest standards of quality.
The Quality Assurance & Control Award recognises Upperton’s deeply embedded quality culture and the role it plays in the successful delivery of client projects. Quality is integrated throughout every stage of development and manufacturing, from project initiation and formulation development through to analytical testing, manufacturing, and release activities. This approach ensures that clients benefit from robust processes, clear communication, and the confidence that quality is never treated as a standalone function but as a core part of project delivery.
Alongside this, retaining the Pharma Contract Services Company of the Year title for a second year is a significant achievement and reflects Upperton’s continued commitment to providing a flexible, responsive, and scientifically driven service to pharmaceutical and biotechnology companies. The award acknowledges the company’s ability to support complex development programmes while building strong, collaborative partnerships with clients at every stage of the drug development journey.
Upperton’s cross-functional teams work closely together to ensure quality considerations are built into every decision, enabling programmes to progress efficiently while maintaining the highest standards of compliance, scientific rigour, and patient safety.
Upperton has continued to strengthen its reputation as a trusted CDMO partner by combining scientific expertise, responsive project management, and a commitment to delivering high-quality outcomes for clients. This integrated approach enables the company to support a diverse range of development programmes, helping innovators navigate the complexities of pharmaceutical development whilst maintaining focus on speed, quality, and successful project outcomes.
Winning both awards further reinforces Upperton’s position as a leading UK CDMO and highlights the company’s ongoing commitment to excellence in both client service and quality delivery.